These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37147150)

  • 61. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group.
    Lerman DM; Monument MJ; McIlvaine E; Liu XQ; Huang D; Monovich L; Beeler N; Gorlick RG; Marina NM; Womer RB; Bridge JA; Krailo MD; Randall RL; Lessnick SL;
    Pediatr Blood Cancer; 2015 May; 62(5):759-65. PubMed ID: 25464386
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study.
    Jeong S; Park YJ; Yun W; Lee ST; Choi JR; Suh C; Jo JC; Cha HJ; Jeong JY; Chang H; Cha YJ; Kim H; Park MJ; Song W; Cho EH; Jeong EG; Lee J; Park Y; Lee YS; Kim DJ; Lee HS
    Sci Rep; 2020 Aug; 10(1):13359. PubMed ID: 32770099
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Phenotypic alterations in Rb pathway have more prognostic influence than p53 pathway proteins in oral carcinoma.
    Jayasurya R; Sathyan KM; Lakshminarayanan K; Abraham T; Nalinakumari KR; Abraham EK; Nair MK; Kannan S
    Mod Pathol; 2005 Aug; 18(8):1056-66. PubMed ID: 15731778
    [TBL] [Abstract][Full Text] [Related]  

  • 64. No evidence of cell cycle dysregulation in mantle cell lymphoma in vivo.
    Vogt N; Abramov D; Koch K; Masqué-Soler N; Szczepanowski M; Klapper W
    Leuk Lymphoma; 2015 Jul; 56(7):2134-40. PubMed ID: 25315075
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Clinicopathologic features and prognosis of mantle cell lymphoma: an analysis of 349 cases].
    Hou WH; Wei P; Xie JL; Zheng YY; Zhang YL; Zhou XG
    Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):417-422. PubMed ID: 29886584
    [No Abstract]   [Full Text] [Related]  

  • 66. Immunohistochemical detection of cdc2 is useful in predicting survival in patients with mantle cell lymphoma.
    Hui D; Reiman T; Hanson J; Linford R; Wong W; Belch A; Lai R
    Mod Pathol; 2005 Sep; 18(9):1223-31. PubMed ID: 15933757
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical Effect of Driver Mutations of
    Gu Y; Ji Y; Jiang H; Qiu G
    Genet Test Mol Biomarkers; 2020 Dec; 24(12):777-788. PubMed ID: 33347393
    [No Abstract]   [Full Text] [Related]  

  • 68. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.
    Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C
    Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14.
    Gallo M; Cacheux V; Vincent L; Bret C; Tempier A; Guittard C; Macé A; Leventoux N; Costes V; Szablewski V
    Virchows Arch; 2016 Dec; 469(6):697-706. PubMed ID: 27605053
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme.
    Kraus JA; Glesmann N; Beck M; Krex D; Klockgether T; Schackert G; Schlegel U
    J Neurooncol; 2000 Jun; 48(2):89-94. PubMed ID: 11083071
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb.
    Grønbaek K; Nedergaard T; Andersen MK; thor Straten P; Guldberg P; Møller P; Zeuthen J; Ebbe Hansen N; Hou-Jensen K; Ralfkiaer E
    Leukemia; 1998 Aug; 12(8):1266-71. PubMed ID: 9697882
    [TBL] [Abstract][Full Text] [Related]  

  • 72. TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma.
    Obr A; Procházka V; Jirkuvová A; Urbánková H; Kriegova E; Schneiderová P; Vatolíková M; Papajík T
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):762-768. PubMed ID: 30146365
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Association of SOX11 gene expression withclinical features and prognosis of mantle cell lymphoma.
    He JX; Xi YF; Su LP; Gao N; Xu EW; Xie LW; Wang LY; Zheng YP; Han WE; Chang J; Wang HW
    Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2556-2563. PubMed ID: 29771407
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma.
    Yang G; Rajadurai A; Tsao H
    J Invest Dermatol; 2005 Dec; 125(6):1242-51. PubMed ID: 16354195
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prognostic significance of CDKN2A/B deletions in acute lymphoblastic leukaemia: a meta-analysis.
    Zhang W; Kuang P; Liu T
    Ann Med; 2019 Feb; 51(1):28-40. PubMed ID: 30592434
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.
    Smeds J; Berggren P; Ma X; Xu Z; Hemminki K; Kumar R
    Carcinogenesis; 2002 Apr; 23(4):645-55. PubMed ID: 11960918
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The
    Han M; Yamaguchi S; Onishi M; Fujii T; Hosoya M; Wen X; Kido H; Kato S
    Anticancer Res; 2022 May; 42(5):2277-2288. PubMed ID: 35489754
    [TBL] [Abstract][Full Text] [Related]  

  • 78. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
    Mareckova A; Malcikova J; Tom N; Pal K; Radova L; Salek D; Janikova A; Moulis M; Smardova J; Kren L; Mayer J; Trbusek M
    Leuk Lymphoma; 2019 Jun; 60(6):1420-1428. PubMed ID: 30626249
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
    [TBL] [Abstract][Full Text] [Related]  

  • 80. P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment.
    Striefler JK; Sinn M; Pelzer U; Jühling A; Wislocka L; Bahra M; Sinn BV; Denkert C; Dörken B; Oettle H; Riess H; Bläker H; Lohneis P
    Pathol Res Pract; 2016 Aug; 212(8):726-34. PubMed ID: 27461834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.